Stay updated on Setmelanotide in Rare Genetic Obesity: Phase 2 Clinical Trial
Sign up to get notified when there's something new on the Setmelanotide in Rare Genetic Obesity: Phase 2 Clinical Trial page.

Latest updates to the Setmelanotide in Rare Genetic Obesity: Phase 2 Clinical Trial page
- Check6 days agoChange DetectedNo significant content changes detected; observed differences are minor UI/layout adjustments that do not affect the information presented for the trial. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check14 days agoChange DetectedRevision: v3.4.2 is now displayed, and the older government funding/operating-status notices were removed; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a government-funding notice informing users about potential delays and the NIH Clinical Center's status, with guidance to check cc.nih.gov and opm.gov for current operations. Updated the site revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check28 days agoChange DetectedAdded a Show glossary control and updated metadata to display 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the site revision 'Revision: v3.4.0'. The previous items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.1%

- Check42 days agoChange DetectedMinor site revision updates were applied, adding Revision: v3.3.4 and removing Revision: v3.3.3. The study details and eligibility criteria remain unchanged.SummaryDifference0.0%

- Check56 days agoChange DetectedNo additions or deletions were detected on the page based on the provided screenshot and text. The page content appears unchanged.SummaryDifference0.1%

Stay in the know with updates to Setmelanotide in Rare Genetic Obesity: Phase 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Setmelanotide in Rare Genetic Obesity: Phase 2 Clinical Trial page.